Natera Debt to Equity Ratio 2014-2023 | NTRA
Current and historical debt to equity ratio values for Natera (NTRA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Natera debt/equity for the three months ending December 31, 2023 was 0.37.
| Natera Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $0.68B | $0.77B | 0.88 |
| 2023-09-30 | $0.66B | $0.79B | 0.84 |
| 2023-06-30 | $0.65B | $0.60B | 1.09 |
| 2023-03-31 | $0.67B | $0.65B | 1.03 |
| 2022-12-31 | $0.69B | $0.71B | 0.98 |
| 2022-09-30 | $0.65B | $0.36B | 1.79 |
| 2022-06-30 | $0.62B | $0.45B | 1.40 |
| 2022-03-31 | $0.60B | $0.54B | 1.11 |
| 2021-12-31 | $0.58B | $0.65B | 0.89 |
| 2021-09-30 | $0.55B | $0.76B | 0.73 |
| 2021-06-30 | $0.55B | $0.30B | 1.84 |
| 2021-03-31 | $0.52B | $0.37B | 1.40 |
| 2020-12-31 | $0.45B | $0.49B | 0.92 |
| 2020-09-30 | $0.44B | $0.54B | 0.82 |
| 2020-06-30 | $0.42B | $0.30B | 1.38 |
| 2020-03-31 | $0.30B | $0.26B | 1.16 |
| 2019-12-31 | $0.30B | $0.28B | 1.09 |
| 2019-09-30 | $0.30B | $0.09B | 3.49 |
| 2019-06-30 | $0.29B | $0.09B | 3.12 |
| 2019-03-31 | $0.26B | $0.01B | 51.44 |
| 2018-12-31 | $0.24B | $0.03B | 7.34 |
| 2018-09-30 | $0.22B | $0.06B | 3.90 |
| 2018-06-30 | $0.22B | $-0.02B | -9.82 |
| 2018-03-31 | $0.22B | $-0.00B | -57.41 |
| 2017-12-31 | $0.19B | $0.03B | 7.44 |
| 2017-09-30 | $0.17B | $0.03B | 5.76 |
| 2017-06-30 | $0.11B | $0.05B | 2.11 |
| 2017-03-31 | $0.10B | $0.07B | 1.39 |
| 2016-12-31 | $0.10B | $0.11B | 0.98 |
| 2016-09-30 | $0.10B | $0.14B | 0.73 |
| 2016-06-30 | $0.10B | $0.16B | 0.60 |
| 2016-03-31 | $0.08B | $0.18B | 0.46 |
| 2015-12-31 | $0.08B | $0.19B | 0.44 |
| 2015-09-30 | $0.06B | $0.21B | 0.27 |
| 2015-06-30 | $0.06B | $0.04B | 1.49 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.00B | 0.00 | |
| 2014-09-30 | $0.00B | $0.00B | 0.00 |
| 2014-06-30 | $0.00B | $0.00B | 0.00 |
| 2013-12-31 | $0.05B | $0.01B | 3.36 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.049B | $1.083B |
| Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $124.048B | 15.56 |
| Cencora (COR) | United States | $47.467B | 18.94 |
| ICON (ICLR) | Ireland | $25.527B | 24.10 |
| DiDi Global (DIDIY) | China | $23.901B | 0.00 |
| Avantor (AVTR) | United States | $17.269B | 23.79 |
| Viatris (VTRS) | United States | $13.856B | 3.96 |
| CochLear (CHEOY) | $13.551B | 0.00 | |
| Revvity (RVTY) | United States | $12.684B | 22.08 |
| Charles River Laboratories (CRL) | United States | $12.333B | 22.48 |
| Medpace Holdings (MEDP) | United States | $12.318B | 40.53 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.750B | 0.00 |
| Solventum (SOLV) | United States | $10.961B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
| HealthEquity (HQY) | United States | $6.795B | 50.77 |
| Bausch + Lomb (BLCO) | Canada | $5.236B | 20.14 |
| Organon (OGN) | United States | $4.783B | 4.63 |
| Doximity (DOCS) | United States | $4.461B | 33.21 |
| PACS (PACS) | United States | $3.596B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.228B | 30.00 |
| Sotera Health (SHC) | United States | $3.190B | 15.65 |
| Progyny (PGNY) | United States | $3.133B | 52.58 |
| Life Times (LTH) | United States | $2.882B | 31.85 |
| GoodRx Holdings (GDRX) | United States | $2.749B | 139.20 |
| Premier (PINC) | United States | $2.531B | 9.26 |
| Teladoc Health (TDOC) | United States | $2.325B | 0.00 |
| Agilon Health (AGL) | United States | $2.191B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.167B | 7.01 |
| BrightSpring Health Services (BTSG) | United States | $1.845B | 0.00 |
| Agiliti (AGTI) | United States | $1.374B | 22.44 |
| Establishment Labs Holdings (ESTA) | $1.344B | 0.00 | |
| NovoCure (NVCR) | Jersey | $1.328B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $0.979B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.776B | 8.03 |
| Embecta (EMBC) | United States | $0.627B | 4.14 |
| Auna S.A (AUNA) | Luxembourg | $0.558B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.542B | 0.00 |
| Enhabit (EHAB) | United States | $0.510B | 46.23 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.502B | 0.00 |
| LifeMD (LFMD) | United States | $0.450B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.423B | 0.00 |
| CareDx (CDNA) | United States | $0.413B | 0.00 |
| Beauty Health (SKIN) | United States | $0.389B | 0.00 |
| MultiPlan (MPLN) | United States | $0.375B | 0.00 |
| DocGo (DCGO) | United States | $0.367B | 58.67 |
| ModivCare (MODV) | United States | $0.353B | 4.68 |
| Sera Prognostics (SERA) | United States | $0.326B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.308B | 0.00 |
| Sharecare (SHCR) | United States | $0.277B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.265B | 0.00 |
| Biodesix (BDSX) | United States | $0.145B | 0.00 |
| So-Young (SY) | China | $0.121B | 40.67 |
| Oncology Institute (TOI) | United States | $0.089B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.077B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
| NeueHealth (NEUE) | United States | $0.053B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
| Nutex Health (NUTX) | United States | $0.033B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.028B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.020B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.014B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.014B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.007B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.006B | 0.00 |
| Assure Holdings (IONM) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |